Roschewski et al. (17) showed that some severe COVID-19 patients receiving acalabrutinib had improved oxygenation and reduced CRP and plasma IL-6, suggesting that BTK inhibitors could be repurposed for diseases involving excessive inflammation. The gene discussed is IL6; the disease is COVID-19.